Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Stella Pharma Corp. (4888:JPX), powered by AI.
Stella Pharma Corp. is currently trading at ¥334. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Stella Pharma Corp. on Alpha Lenz.
Stella Pharma Corp.'s P/E ratio is -79.2.
“Stella Pharma Corp. trades at a P/E of -79.2 (undervalued) with modest ROE of -5.0%. 3Y revenue CAGR of 112.5% highlights clear growth momentum.”
Ask for details →Stella Pharma Corp. is a prominent player in the pharmaceutical industry, focusing on the development, production, and distribution of medical products and therapies. The company's primary mission is to address unmet medical needs through innovative and effective solutions, targeting a wide range of health conditions. Stella Pharma's product portfolio spans across various therapeutic areas, including oncology, cardiology, immunology, and infectious diseases, showcasing its dedication to improving patient outcomes globally. With a robust research and development pipeline, Stella Pharma invests heavily in cutting-edge technologies and partnerships, enhancing its capability to bring novel treatments to market. The company operates globally, collaborating with medical institutions, research organizations, and healthcare providers to ensure comprehensive healthcare solutions. Its market significance is underscored by its commitment to maintaining high standards of quality, safety, and efficacy in all its products, reinforcing trust and reliability among healthcare professionals and patients alike. As the healthcare landscape evolves, Stella Pharma continues to play a vital role in shaping the future of medicine through its relentless pursuit of innovation and excellence.
“Stella Pharma Corp. trades at a P/E of -79.2 (undervalued) with modest ROE of -5.0%. 3Y revenue CAGR of 112.5% highlights clear growth momentum.”
Ask for details →Stella Pharma Corp. (ticker: 4888) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 43 employees. Market cap is $11.1B.
The current price is 334 with a P/E ratio of -79.18x and P/B of 3.48x.
ROE is -5.04% and operating margin is -9.39%. Annual revenue is $961M.